Suppr超能文献

静脉血栓栓塞概述。

Overview of venous thromboembolism.

机构信息

Trauma and Orthopaedic Surgery Department, Carlos Haya Regional University Hospital, Málaga, Spain.

出版信息

Drugs. 2010 Dec 14;70 Suppl 2:3-10. doi: 10.2165/1158583-S0-000000000-00000.

Abstract

Thrombosis occurs at sites of injury to the vessel wall, by inflammatory processes leading to activation of platelets, platelet adherence to the vessel wall and the formation of a fibrin network. A thrombus that goes on to occlude a blood vessel is known as a thromboembolism. Venous thromboembolism begins with deep vein thrombosis (DVT), which forms in the deep veins of the leg (calf) or pelvis. In some cases, the DVT becomes detached from the vein and is transported to the right-hand side of the heart, and from there to the pulmonary arteries, giving rise to a pulmonary embolism (PE). Certain factors predispose patients toward the development of venous thromboembolism (VTE), including surgery, trauma, hospitalization, immobilization, cancer, long-haul travel, increased age, obesity, major medical illness and previous VTE; in addition, there may also be a genetic component to VTE. VTE is responsible for a substantial number of deaths per annum in Europe. Anticoagulants are the mainstay of both VTE treatment and VTE prevention, and many professional organizations have published guidelines on the appropriate use of anticoagulant therapies for VTE. Treatment of VTE aims to prevent morbidity and mortality associated with the disease, and any long-term complications such as VTE recurrence or post-thrombotic syndrome. Generally, guidelines recommend the use of low molecular weight heparins (LMWH), unfractionated heparin (UFH) or fondaparinux for the pharmacological prevention and treatment of VTE, with the duration of therapy varying according to the baseline characteristics and risk profile of the individual. Despite evidence showing that the use of anticoagulation prevents VTE, the availability of several convenient, effective anticoagulant therapies and the existence of clear guideline recommendations, thromboprophylaxis is underused, particularly in patients not undergoing surgery. Greater adherence to guideline-recommended therapies, such as LMWH, which can be administered on an outpatient basis, should reduce the mortality associated with this preventable disease.

摘要

血栓形成发生于血管壁损伤部位,通过导致血小板激活、血小板黏附于血管壁和纤维蛋白网络形成的炎症过程。导致血管阻塞的血栓称为血栓栓塞。静脉血栓栓塞症始于深静脉血栓形成(DVT),其在腿部(小腿)或骨盆的深静脉中形成。在某些情况下,DVT 会从静脉上脱落并被输送到右心房,然后输送到肺动脉,导致肺栓塞(PE)。某些因素使患者易发生静脉血栓栓塞症(VTE),包括手术、创伤、住院、固定不动、癌症、长途旅行、年龄增长、肥胖、重大疾病和既往 VTE;此外,VTE 可能也存在遗传因素。VTE 每年在欧洲导致大量死亡。抗凝剂是 VTE 治疗和 VTE 预防的主要方法,许多专业组织已经发布了关于 VTE 抗凝治疗适当使用的指南。VTE 的治疗旨在预防与疾病相关的发病率和死亡率,以及任何长期并发症,如 VTE 复发或血栓后综合征。一般来说,指南建议使用低分子量肝素(LMWH)、未分馏肝素(UFH)或磺达肝癸钠进行 VTE 的药理学预防和治疗,治疗持续时间根据个体的基线特征和风险状况而有所不同。尽管有证据表明抗凝治疗可预防 VTE,但有几种方便有效的抗凝治疗方法可用,并且存在明确的指南建议,但血栓预防的应用不足,尤其是在未接受手术的患者中。更严格地遵循指南推荐的治疗方法,如可以在门诊进行的 LMWH,可以降低与这种可预防疾病相关的死亡率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验